The University of Queensland, UQ Centre for Clinical Research, Brisbane, Queensland, Australia.
Herston Infectious Diseases Institute, Herston, Brisbane, Queensland, Australia.
Clin Infect Dis. 2024 Aug 16;79(2):502-515. doi: 10.1093/cid/ciae234.
Evidence about the clinical impact of rapid diagnostic tests (RDTs) for the diagnosis of bloodstream infections is limited, and whether RDT are superior to conventional blood cultures (BCs) embedded within antimicrobial stewardship programs (ASPs) is unknown.
We performed network meta-analyses using results from studies of patients with bloodstream infection with the aim of comparing the clinical impact of RDT (applied on positive BC broth or whole blood) to conventional BC, both assessed with and without ASP with respect to mortality, length of stay (LOS), and time to optimal therapy.
Eighty-eight papers were selected, including 25 682 patient encounters. There was an appreciable amount of statistical heterogeneity within each meta-analysis. The network meta-analyses showed a significant reduction in mortality associated with the use of RDT + ASP versus BC alone (odds ratio [OR], 0.72; 95% confidence interval [CI], .59-.87) and with the use of RDT + ASP versus BC + ASP (OR, 0.78; 95% CI, .63-.96). No benefit in survival was found associated with the use of RDT alone nor with BC + ASP compared to BC alone. A reduction in LOS was associated with RDT + ASP versus BC alone (OR, 0.91; 95% CI, .84-.98) whereas no difference in LOS was shown between any other groups. A reduced time to optimal therapy was shown when RDT + ASP was compared to BC alone (-29 hours; 95% CI, -35 to -23), BC + ASP (-18 hours; 95% CI, -27 to -10), and to RDT alone (-12 hours; 95% CI, -20 to -3).
The use of RDT + ASP may lead to a survival benefit even when introduced in settings already adopting effective ASP in association with conventional BC.
关于快速诊断检测(RDT)在诊断血流感染方面的临床影响的证据有限,并且 RDT 是否优于嵌入抗菌药物管理计划(ASP)中的常规血培养(BC)尚不清楚。
我们进行了网络荟萃分析,使用了血流感染患者研究的结果,旨在比较 RDT(应用于阳性 BC 肉汤或全血)与常规 BC 的临床影响,评估有无 ASP 对死亡率、住院时间(LOS)和最佳治疗时机的影响。
共选取了 88 篇论文,包括 25682 例患者。每个荟萃分析中都存在相当大的统计学异质性。网络荟萃分析显示,与单独使用 BC 相比,使用 RDT+ASP 与死亡率降低相关(比值比[OR],0.72;95%置信区间[CI],0.59-0.87),与使用 RDT+ASP 相比,使用 BC+ASP 与死亡率降低相关(OR,0.78;95% CI,0.63-0.96)。与单独使用 RDT 或 BC+ASP 相比,单独使用 BC 并未发现生存获益。与单独使用 BC 相比,RDT+ASP 与 LOS 降低相关(OR,0.91;95% CI,0.84-0.98),而任何其他组之间的 LOS 差异均无统计学意义。与单独使用 BC 相比,使用 RDT+ASP 可缩短最佳治疗时机(-29 小时;95% CI,-35 至-23),使用 BC+ASP 可缩短最佳治疗时机(-18 小时;95% CI,-27 至-10),使用 RDT 可缩短最佳治疗时机(-12 小时;95% CI,-20 至-3)。
即使在已经采用有效的 ASP 与常规 BC 联合应用的环境中引入 RDT+ASP,也可能带来生存获益。